Aligos Therapeutics, Inc. (ALGS) Free cash flow 2019–2024
Aligos Therapeutics, Inc. (ALGS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$80.9MFY2024 · since FY2019: -$49.6M → -$80.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$80.9M | -2.4% |
| FY2023 | -$79.0M | +1.6% |
| FY2022 | -$80.3M | +31.1% |
| FY2021 | -$116.6M | -52.7% |
| FY2020 | -$76.3M | -54.0% |
| FY2019 | -$49.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALGS financial trends
ALGS RevenueALGS Net incomeALGS Net marginALGS Gross profitALGS Gross marginALGS Operating incomeALGS Operating marginALGS Operating cash flowALGS Capital expendituresALGS Return on equityALGS Stock buybacksALGS Dividends paidALGS Total assetsALGS Total liabilitiesALGS Shareholders’ equityALGS overview →